In a phase 2 trial, firsekibart — an IL-1 beta antibody — outperforms colchicine in preventing acute gout flares over 12 weeks in patients with gouty arthritis initiating urate-lowering therapy.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/new-antibody-therapy-shows-promise-preventing-gout-flares-2025a1000x6q?src=rss
Author :
Publish date : 2025-11-27 08:59:00
Copyright for syndicated content belongs to the linked Source.
